India's antitrust regulator said on Thursday it had made an initial observation that Sun Pharmaceutical Industries Ltd's agreed $3.2 billion acquisition of Ranbaxy Laboratories Ltd could hurt competition, asking the companies to provide more details.

The Competition Commission of India (CCI) is still investigating the deal, but has formed a "prima facie opinion that the combination is likely to have an appreciable adverse effect on competition," according to a government statement on Thursday and a document posted on the regulator's website.

Sun and Ranbaxy have been asked by the regulator to publish details of the deal within 10 working days on their websites as well as in four national newspapers. The CCI also sought comments or objections from the public on the proposed deal.

Sun Pharma agreed in April to buy Ranbaxy from Japan's Daiichi Sankyo Ltd to create the world's fifth-largest maker of generic drugs. Both companies have previously said they expect to complete the deal by December.

Related Articles

Features

EXPLAINER: Could proposed India competition rules usher new Era of antitrust regulation?

by Nimitt Dixit |

The Competition Commission of India (CCI), the country’s antitrust regulator, has come out with a draft framework for commitment and settlement of cases, as well as a draft merger control guideline which, when finalised and enforced, are likely to substantially over-haul antitrust regulation in the country.

Appointments

Stephenson Harwood lands Hill Dickinson’s former Asia regulatory head

by Mari Iwata |

Stephenson Harwood has hired Jonathan Goacher, the former head of regulatory for Asia at Hill Dickinson, as a partner in Singapore.

Appointments

Hong Kong’s Hauzen recruits former Deutsche lawyer as partner

by Mary Iwata |

Hong Kong law firm Hauzen has hired corporate and regulatory lawyer Andy Lau as a partner. Lau’s most recent role was at Deutsche Bank, where he was senior legal counsel between 2018 and 2021.